Lung cancer detectability by test, histology, stage, and gender: Estimates from the NLST and the PLCO trials

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 1, 2015, Pages 154-161

  Ten Haaf, Kevin ^a   Van Rosmalen, Joost ^a   De Koning, Harry J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE COURSE; FEMALE; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; SMALL CELL LUNG CANCER; SQUAMOUS CELL LUNG CARCINOMA; THORAX RADIOGRAPHY; CANCER REGISTRY; CANCER STAGING; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; EARLY CANCER DIAGNOSIS; GENDER IDENTITY; LUNG NEOPLASMS; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

AGED; CLINICAL TRIALS AS TOPIC; EARLY DETECTION OF CANCER; FEMALE; GENDER IDENTITY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SEER PROGRAM;

EID: 84921030873     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0745     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, et al. Screening by chest radiograph and lung cancer mortality: The prostate, lung, colorectal, and ovarian (PLCO) randomized trial. JAMA 2011;306: 1865-73.
3. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
4. de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, et al. Benefits and harms of computed tomography lung cancer screening strategies: A comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med 2014;160:311-20.
5. Fracheboud J, Groenewoud JH, Boer R, Draisma G, de Bruijn AE, Verbeek ALM, et al. Seventy-five years is an appropriate upper age limit for population-based mammography screening. Int J Cancer 2006;118: 2020-5.
6. Pinsky PF. An early-and late-stage convolution model for disease natural history. Biometrics 2004;60:191-8.
7. Chien C-R, Chen TH-H. Mean sojourn time and effectiveness of mortality reduction for lung cancer screening with computed tomography. Int J Cancer 2008;122:2594-9.
8. Wu D, Erwin D, Rosner GL. Sojourn time and lead time projection in lung cancer screening. Lung Cancer 2011;72:322-6.
9. Patz EF Jr, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemägi MC, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 2014;174:269-74.
10. Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, et al. National lung screening trial research team. The National Lung Screening Trial: overview and study design. Radiology 2011;258: 243-53.
11. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000;21:273S-309S.
12. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer. cancer.gov) SEER-Stat Database: Incidence -SEER 17 Regs Research Data+ Hurricane Katrina Impacted Louisiana Cases, Nov 2010 Sub (1973-2008 varying) -Linked To County Attributes -Total U.S., 1969-2009 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011 (updated 10/28/2011), based on the November 2010 submission. Accessed Feb 24, 2012.
13. Schultz FW, Boer R, de Koning HJ. Chapter 7: description of MISCAN-Lung, the erasmus MC lung cancer microsimulation model for evaluating cancer control interventions. Risk Anal 2012;32:S85-S98.
14. Meza R, ten Haaf K, Kong CY, Erdogan A, Black WC, Tammemagi MC, et al. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. Cancer 2014;120:1713-24.
15. Jeon J, Meza R, Krapcho M, Clarke LD, Byrne J, Levy DT. Chapter 5: Actual and counterfactual smoking prevalence rates in the U.S. population via microsimulation. Risk Anal 2012;32:S51-S68.
16. Barton RR, Ivey JS Jr. Nelder-Mead simplex modifications for simulation optimization. Manag Sci 1996;42:954-73.
17. McMahon PM, Meza R, Plevritis SK, Black WC, Tammemagi CM, Erdogan A, et al. Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the national lung screening trial using comparative modeling. PLoS One 2014;9:e99978.
18. Heidenreich WF, Luebeck EG, Moolgavkar SH. Some properties of the hazard function of the two-mutation clonal expansion model. Risk Anal 1997;17:391-9.
19. Meza R, Hazelton W, Colditz G, Moolgavkar S. Analysis of lung cancer incidence in the nurses' health and the health professionals' follow-up studies using a multistage carcinogenesis model. Cancer Causes Control 2008;19:317-28.
20. Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone A-M, et al. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 2012;118:2338-66.
21. SEER Stat Fact Sheets: Lung and Bronchus Cancer. [cited Accessed February 22nd 2013. Available from: http://seer.cancer.gov/statfacts/html/lungb.html.
22. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organization; 2000.
23. Eleazar JA, Borczuk AC. Chapter 23: molecular pathology of large cell carcinoma and its precursors. In:Zander DS, editor. Molecular pathology of lung diseases. Springer; 2010. p. 279-92.
24. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society internationalmultidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-85.
25. Pinsky PF, Church TR, Izmirlian G, Kramer BS. The national lung screening trial: Results stratified by demographics, smoking history, and lung cancer histology. Cancer 2013;119:3976-83.
26. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. eds, for the American joint committee on cancer. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.
27. Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, et al. Results of the two incidence screenings in the national lung screening trial. N Engl J Med 2013;369:920-31.
28. Wever EM, Draisma G, Heijnsdijk EAM, Roobol MJ, Boer R, Otto SJ, et al. Prostate-specific antigen screening in the United States vs in the European randomized study of screening for prostate cancer-Rotterdam. J Natl Cancer Inst 2010;102:352-5.
29. Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, et al. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (Seventh) Edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:694-705.
30. van Ballegooijen M, Rutter CM, Knudsen AB, Zauber AG, Savarino JE, Lansdorp-Vogelaar I, et al. Clarifying differences in natural history between models of screening. Med Decis Making 2011;31:540-9.
31. Horeweg N, van der Aalst CM, Thunnissen E, Nackaerts K, Weenink C, Groen HJM, et al. Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial. Am J Respir Crit Care Med 2013;187:848-54.